Bioavailable phosphate
Phosphorus is organically bound and stored as phytate in grains, cereals and seeds. Humans and other non-ruminant animals lack the digestive enzyme phytase that is produced by bacteria in the gut of ruminants, and consequently humans are unable to digest phytate. This results in less than 40% of phosphate from plant sources being bioavailable and the remainder being excreted. By comparison, phosphate derived from animal products such as meat, fish and milk is more readily absorbed, 5 and the absorption of phosphate food additives approaches 100%. These additives are frequently used as food processing aids, as colour and flavour enhancers, to alter food texture and to increase shelf life. Sugary carbonated beverages have added phosphoric acid to sharpen flavour and to slow the growth of moulds and bacteria.
The challenges of calculating dietary phosphate
Depending on the dietary source, approximately 60% of phosphate undergoes gastrointestinal absorption and 95% of the absorbed phosphate is renally excreted unless renal function is severely compromised. Intestinal phosphate absorption is responsive to levels of circulating 1,25-dihydroxyvitamin D and prescribed calcitriol or other vitamin D receptor agonists (VDRAs). These drugs can increase active phosphate absorption to around 80% by increasing intestinal type II sodium-dependent phosphate cotransporter 2b (Npt2b) activity. With this in mind, the current Kidney Disease Improving Global Outcomes (KDIGO) CKD-mineral and bone disorder (MBD) guidelines no longer recommend the use of calcitriol/VDRAs for patients with CKD stages 3 to 5 and moderate hyperparathyroidism, instead suggesting that these agents be reserved for severe and progressive hyperparathyroidism. 6 The varying bioavailability of phosphate between food sources and the effect of prescribed drugs on phosphate absorption can lead to the dietetic assessment of phosphate intake being inaccurate. In a study by Oenning et al. that compared dietary phosphate content using standard food tables and chemical analyses, 7 food tables underestimated the phosphate content of diets by approximately 350 mg/day. This inaccuracy was further emphasized in a recent study, which reported that traditional methods of calculating intake from food databases overestimated the true phosphate content of a vegetarian diet by 33%, although a fresh meat and milk product-based diet did match database predictions. 5 For patients with CKD, any reduction of dietary phosphate must be balanced against the maintenance of adequate dietary protein, energy and normal potassium values, which often leads to complex instructions and reduces dietary adherence.
Evidence for restricting phosphate
Restriction of dietary protein, and with it dietary phosphate, slows the progression of renal disease in experimental animal models. 8, 9 In humans, elevated phosphate levels are associated with the development and progression of CKD-MBD, 10 The Modification of Diet in Renal Disease (MDRD) study, 21 was a major initiative to assess decline in kidney function in relation to three levels of protein and phosphate intake (normal, low and very low), and two levels of blood pressure management. In the primary analysis, there were no statistically significant differences in progression between low and usual protein diets, or between low and very low protein diets. The authors concluded that the effect of these dietary prescriptions to patients with mild to moderate renal insufficiency remained uncertain. Further analysis suggested that lower protein diets might slow progression in patients with the most rapid decline in GFR 22 and each decrease in protein intake of 0.2 g/kg per day was associated with a slower mean GFR decline. 23 As a result, the authors suggested a prescribed dietary protein intake of 0.8 g/kg per day for patients with GFR < 25 mL/ min per 1.73 m 2 .
Pedrini et al. 24 performed a systematic review of studies to December 1994 that assessed usual versus low protein dietary restriction in patients with moderate CKD (eGFR <55 mL/min per 1.73m
2 ). That meta-analysis indicated significantly less progression of renal impairment in both non- 19 Moe et al. 5 investigated differences in phosphate absorption between grain-based and meat-based diets that contained equivalent protein and phosphate, and observed higher levels of serum phosphate and FGF23 and lower PTH levels after 1 week of the meat-based diet. Over the short term, very low protein diets may reduce serum FGF23 levels 25 and higher phosphate diets may induce FGF23, 26, 27 which may be attenuated by the addition of the phosphate binder lanthanum carbonate. 28 However, these studies are limited by short duration. Most recently, a long term follow-up of patients enrolled in the MDRD study 29 reported that pre-randomization urinary phosphate levels were not associated with long-term outcomes of ESRD or mortality, although in a fully adjusted model a three-day dietary recall for phosphate did show a modest association to all-cause mortality. The authors suggested that until further studies confirmed or refuted their findings, caution should be used in advising reductions in dietary phosphate and protein intake in patients with CKD.
The chance of such a study is remote.
Improving the management of phosphate control;
'what you eat today walks and talks tomorrow'
In 2013, Dr. Tonelli writing in Kidney International, 30 suggested that a smart phone 'food switch' application (app) could be developed for patients with CKD to help them control their phosphate levels. After scanning the bar code of a product, the app would provide information on the phosphate content (inclusive of additives) of the selected and comparable products, so that consumers could make a more informed choice. Of course, this relies on the availability of an extensive, locally germane food database. With this in mind, we approached the developers of the most downloaded, free of charge Australian dietary app to create a version containing information applicable to patients with CKD. The app contained information on over 50 000 Australian foods obtained from Australian food databases and food product labels. Patients using the app could elect to share data collected by the app with their dietitian or other health professionals, to enable real-time online monitoring of their progress. 
METHODS
After providing volunteers with study information and receiving their informed consent, 25 participants with a normal urinalysis, blood pressure and without a history of kidney disease or use of medications likely to influence urinary sodium or phosphate values were randomly allocated to an intervention or a control group. Next, all participants maintained a food diary for 3 days to assess baseline dietary sodium and phosphate intakes, followed by a 24 h urine sample for volume, creatinine, sodium and phosphate. Participants were then requested to moderately reduce their sodium and phosphate intake for 2 weeks, to daily targets often used for people with ESRD of <100 mmol sodium and <1000 mg phosphate. To achieve this, all participants were provided with a dietary leaflet used in normal clinical care that provided advice on strategies to achieve the reduction. Based on the dietary records, participants were given feedback on their dietary intakes of sodium and phosphate, and provided with individualised advice on reducing that intake to within the target range in a telephone interview of no more than 1 h with a trained dietician. No additional strategies were used in the control group. However, the intervention group were given approximately 30 min instruction by a non-dietician on use of the dietary app to monitor sodium and phosphate targets. The primary outcome was to assess within group change in 24 h urinary phosphate and sodium values between collections at baseline and 2 weeks after commencement of the diet. The estimated sample size for this was 10 participants per arm. Calculation of between group differences (estimated sample size 123 subjects per arm) was outside the scope of this pilot study. The secondary outcome was to compare ease of dietary compliance between the groups using a questionnaire completed by all participants at the conclusion of the dietary intervention. The questionnaire included 11 questions on acceptability and usability of the food diary, five on compliance, five free text questions and for app users, 14 questions on ease of use.
Paired t-tests or Wilcoxon signed rank tests were used to test for differences between baseline and end of the intervention. Independent t-tests or Wilcoxon rank sum tests were used to test for differences between groups. Analyses were conducted by intention to treat and significance was determined by P-values <0.05. Questionnaire responses were recorded by participants using a 5-point Likert scale. Statistical analyses were undertaken using SPSS version 21 (SPSS Inc., Chicago, IL, USA).
RESULTS
Participant demographics and clinical details, dietary intakes calculated from the 3 day food diaries and baseline 24 h urinary values for sodium, phosphate and creatinine did not differ significantly between groups (Table 2) . Baseline sodium and phosphate intakes from the 3 day dietary assessments were close to the 50th percentile of ageadjusted population norms. However, 24 h urinary values of sodium and phosphate, measured as a single batch after the conclusion of the study, were close to the targeted range even before any dietary intervention (Table 2) . Comparison of pre-and post-intervention urinary values indicated trends to reduction in mean sodium and phosphate values that did not reach statistical significance within or between groups (Table 2) or when values for the control and app group were combined to assess change over the period of dietary intervention. Comparing questionnaire responses, app users referred to information on the app more frequently than the control group participants referred to written instructions, app users found referring to the app more convenient, felt they learned more new information, were more motivated to maintain the diet and were more likely to recommend their information source to family or friends (all P < 0.05), with trends to confidence in improving eating habits (P = 0.06), ease of use (P = 0.07) and fewer non-compliant days (P = 0.08) ( Table 2 ). In the free text section, six control participants felt they lacked access to sufficient information, while no app users indicated that they lacked information.
DISCUSSION
The pilot study suggested that participants using the app, which gave them immediate access to the sodium, phosphate, potassium and nutrient content of their foods, had a better experience of the restricted diet. Their greater motivation and self-assessed increase in knowledge of food sources was encouraging. These results can be contrasted with a study of 279 patients in 14 long-term dialysis facilities with persistently elevated phosphate levels. 31 Patients were allocated to usual care or intervention that included specific instruction, handouts of preferred foods and foods to avoid and additional telephone reinforcement. Serum phosphate levels decreased at 3 months in the intervention group and food knowledge scores improved in both. However, there was no significant difference in food knowledge between control and interventional groups as noted in our study. Nevertheless, it is important to emphasize that before use of the app can be endorsed in research or with groups such as patients with CKD, further studies would be required to determine whether the app assists these patients to achieve their nutrient targets. The renal app is now available in Australasia, with approximately 450 downloads in the first 6 months since its release. A screen shot of a sample breakfast is included (Fig. 1) . Further modifications will differentiate foods high in organic and inorganic phosphate and provide the 'food switch' capacity suggested by Dr. Tonelli in 2013. 30 
CONCLUSION
In ESRD, when phosphate homeostasis is no longer attainable through endogenous responses, a low phosphate, high protein intake has been associated with reduced mortality, but extremely low dietary phosphate combined with a low protein intake may produce worse outcomes. This equipoise is not achieved by many patients. Based on the available evidence, encouragement to eat grain and vegetable-based meals with lower inorganic phosphate, reduced phosphate additives and high-value protein is unlikely to have adverse effects and may have benefits for most people with CKD. Reduced reliance on calcitriol or other VDRAs to suppress PTH, and an acceptance of moderately increased PTH levels in the later stages of CKD, will also lead to reduced intestinal phosphate absorption and may improve phosphate balance. Although based on weak clinical evidence, it appears preferable to target treatment towards overt hyperphosphataemia in CKD stages 3-5, rather than targeting values of serum phosphate in the normal range. As well as being more attainable, this would reduce adverse effects of phosphate binder therapy, including hypercalcaemia associated with calcium-based binders. Public advocacy for the disclosure on packaged food labels of all phosphate additives, which are the source of highly absorbed phosphate, would be a real benefit to consumers. In addition, a renal dietary app may encourage some users to understand and improve their food choices and dietary compliance.
